Survey: Government Least Likely to Be Source of Information on Cannabis

Government sources are the least likely sources utilized by individuals when seeking information about cannabis, according to a study published this month in the Journal of Cannabis Research. The researchers found just 4.7% of survey respondents used government resources for cannabis information.  

The survey included 1,161 respondents, of which 27% reported consuming cannabis in the past year. Friends and family were the most common information sources for those surveyed (35.6%) followed by websites (33.7%). Healthcare providers were utilized for cannabis information by 9.3% of respondents – but 16.4% of those surveyed who were registered medical cannabis patients said they obtained their information from a healthcare provider – while dispensary employees were the source of information about cannabis by 8.6% of respondents.   

“As cannabis accessibility increases and legality continues changing, there is a strong need for better clinician education, improved public health outreach, and improved communication between patients and clinicians about cannabis.” — “Cannabis-related information sources among US residents: A probability-weighted nationally representative survey,” Journal of Cannabis Research, 10/1/24 

The survey included adults 18 and older. Gender demographics among the survey-takers were nearly even, with 51% identifying as female and 49% identifying as male. The researchers note that “past year cannabis use was positively associated with all information sources except government agencies and popular media articles.”  

End


Cannabis Tech Firm Formerly Valued at $700M Going Out of Business

Eaze Technologies Inc., the San Francisco-based cannabis technology giant that was once valued at more than $700 million, is laying off more than 500 workers and closing down later this year, SF Gate reports. The company launched in 2014 and offers on-demand delivery services in California and Michigan.

Eaze CEO Cory Azzalino said in a LinkedIn post on Monday that the company sold its assets at auction in early August and had begun “winding down operations” with plans to be shuttered completely by December 31.

“As we proceed with the transfer of the company’s assets, we will provide more clarity on the timing of events. We anticipate being able to provide an update on next steps on or around November 15, 2024. For employees represented by UFCW, we have already provided the Union notice and expect to engage with them in bargaining discussions regarding the effects of the wind down.” – Azzalino, in a letter to employees

Jim Araby, a vice president at the United Food Commercial Workers International Union (UFCW), told SF Gate that Eaze’s closure — and the resulting loss of nearly 500 union jobs — “should be a wake up call to the state legislators and the government that more action needs to be taken.”

The folding of Eaze marks the latest downfall of a California cannabis industry giant as the market continues to struggle against over-regulation and competition from illicit cannabis sources:

  • California-based MedMen, which once held retail dispensary licenses in state markets across the U.S., filed for bankruptcy earlier this year, entering receivership with more than $410 million in liabilities owed.
  • Last June, Herbl — formerly among the largest cannabis distributors in California — shut down operations and entered receivership.

In 2021, two former Eaze consultants were found guilty of having defrauded banks into processing more than $150 million in cannabis purchases, and were sentenced to prison.

End


Arkansas Medical Cannabis Initiative Has Signatures to Qualify for November Ballot

The Director of Elections at the Arkansas Secretary of State’s office said last week the petition to expand the state’s medical cannabis program has enough signatures to qualify for the November ballot, THV11 reports.

“I can confirm that no less than 91,000 signatures were verified pursuant to the counting as ordered by the Arkansas Supreme Court.” — Leslie Bellamy, director of elections, in the report

The admission came after Secretary of State John Thurston said previously that the signature-gathering effort by Arkansans for Patient Access, the group behind the medical cannabis expansions campaign, had fallen more than 2,000 signatures short of the 91,000 signature threshold to qualify for the ballot.

But the campaign appealed, arguing that Thurston failed to consider signatures collected during a “cure period” granted after the campaign initially came up short on signatures in July but, per state law, earned an extra month to pursue its goal. The Supreme Court ultimately ordered the secretary of state to verify the remaining signatures.

The amendment itself sought to improve patient access by allowing more medical professionals to certify people to the program and allowing medical cannabis ID certifications to be conducted via telemedicine. Additionally, the amendment would have legalized home grows for patients, allowed for out-of-state patient IDs, increased the patient registration period from one year to three years, and removed patient program application fees.

End


Interview: Federal Rescheduling of Cannabis

Morgan Fox: The Symbolism and Reality of Federal Cannabis Rescheduling

The DEA’s public hearing regarding changing the classification for cannabis is scheduled for December 2nd, but what would Schedule III really mean for the industry as it exists today? In this episode of the Ganjapreneur Podcast, host TG Branfalt sits down with Morgan Fox, Political Director for NORML, one of the nation’s leading cannabis advocacy organizations founded in 1970. Morgan brings over a decade of experience in cannabis policy reform to the conversation, discussing the Biden administration’s announcement on cannabis rescheduling and the real-world impact it may—or may not—have on the cannabis industry, consumers, and criminal justice.

Morgan also sheds light on the intricate political dynamics that influence cannabis policy at the federal level, from potential barriers in the rescheduling process to the ongoing battle for meaningful reform in Congress. Whether you’re interested in cannabis law, industry tax issues, or the future of cannabis legalization, this episode offers deep insights into the current state and future possibilities of cannabis policy in the United States.

Find the episode wherever you listen to podcasts, or listen via the media player below! (Scroll down for the full transcript.)


Listen to the episode:


Read the full transcript:

Editor’s note: this transcript was auto-generated and may contain errors

Commercial:

The Ganjapreneur Podcast is made possible by over 500 cannabis industry service providers in Ganjapreneur’s Cannabis Business Index. At some point, every plant touching brand experiences the stigma that many industries still have to toward cannabis going strong. Since 2015, our business index is the most comprehensive and frequently visited directory for cannabis friendly services on the internet, saving you the time and hassle of sifting through uninformed and unwelcoming providers with categories for everything from business financing to extraction equipment to interior designers and public relations. You’ll find every kind of specialist and business service you could ever need. Check out the business index today at ganjapreneur.com/businesses.

TG Branfalt:

Hey there, I’m your host, TG Branfalt, and this is the Ganjapreneur.com podcast where we try to bring you actionable information and normalized cannabis through the stories of entrepreneurs, activists, and industry stakeholders. Today I am joined by Morgan Fox. He is the political Director for NORML, which has advocated for cannabis policy reforms since 1970. How are we doing this afternoon, Morgan?

Morgan Fox:

Doing great. How about yourself?

TG Branfalt:

Cool, man. Cool. We are recording this interview’s on the heels of the Biden administration announcing that they would reschedule cannabis from a Schedule one drug to a Schedule three drug. But before we get into that, my man, I know you’ve been on the show before, but just remind people about your background and how long you’ve been at NORML and what your job entails.

Morgan Fox:

Sure. So I’ve been involved in a cannabis policy reform professionally since 2008. Started out at Marijuana Policy Project as an intern with basically just a backpack, a guitar to skateboard, rolling down to DC from Cleveland and was offered a full-time position shortly after that. Spent about 10 years at Marijuana Policy Project finishing up there as their director of communications before moving over to the National Cannabis Industry Association as their media relations director, and then spent a little under four years there before pivoting to NORML and working primarily in federal policy and lobbying. Although these days I wear a lot of different hats within the organization, but I really wanted to move more towards a consumer advocacy perspective and NORML was a perfect opportunity for do that. So really happy to be at this organization doing the work that’s been going on for more than 50 years now, as you said, a very momentous time.

TG Branfalt:

Yeah. So let’s talk about that a bit. There’s a lot of punditry going on, a lot of what will this do in your eyes as political director for NORML in NORML’s eyes? What will Federal do sort of broadly and for the cannabis industry at large?

Morgan Fox:

Before we get into that, I think it’s really important that we talk about the timing.

TG Branfalt:

All right.

Morgan Fox:

And because I think a lot of people might have the misconception that because of the Biden administration announcements and because of a lot of the rumors that have been swirling around on the internet, et cetera, that this is a done deal and it is not. DEA has final jurisdiction over this call unless Congress acts. Now, obviously, the administration can put pressure on federal agencies to enact the policy changes that it wants to see, but unfortunately, the Biden administration is not really in a position to do that with an election coming up with increasing partisan ranker going on within Congress and just generally in the United States, but also when we’re seeing pretty much daily hearings in Congress about weaponization of federal agencies for political purposes, the Biden administration really isn’t in a position to put too much pressure on the DEA to either expedite this ruling or to rule in any particular way despite all of the research that backs up this move, this is one of the problems with calling for complete descheduling. So when this process began with the formal announcement from the DEA and the Department of Justice that there was a notice of prose rulemaking, the White House office had 60 days to approve that and move it further down the process, they did that within a couple of days, which was not entirely unexpected, but still a really good sign that the administration supports this move and that is willing to throw its way behind it. Bureaucratically now we’re entering into the public comment period, which starts officially tomorrow, supposedly and will last

TG Branfalt:

May 21st. May 21st,

Morgan Fox:

Exactly. And will last approximately 60 days normally. And our allies are going to be trying to flood the comment section with information that the DEA really needs to make a decision on this because if you noticed, and the notice of proposed rulemaking was almost a hundred pages long and essentially laid out all of the reasons why they are going to ignore the information that HHS sent them, which a lot of people are saying is binding, but as soon as the public comment period begins is no longer binding, it has to be given significant deference. But that’s a very subjective term.

TG Branfalt:

Lemme just ask you real quick is how much of a difference would, I guess, as you put it, flooding this public comment? What kind of impact could that have?

Morgan Fox:

Well, I think it could have a significant impact because all this stuff goes on the record, and we’re going to be working with physicians, with patients, with average citizens, with advocacy groups to try to get the best information submitted during that public comment to make sure that people are seeing the real science and also seeing the real impacts that rescheduling could have or that rather not that rescheduling could have, but that keeping cannabis in Schedule one will continue to have. But that’s a very important point, but that process only lasts 60 days, so that’s going to be starting on May 21st. Supposedly there might be a delay of a couple of days, but it seems like the process is moving already after that 60 days. There is an administrative review process, so for the first 30 days of the comment, people can request hearings. I am fairly certain that those hearings will be granted because DEA wants more opportunity to show why it disagrees with the recommendations based on scientific information to not reschedule cannabis.

TG Branfalt:

And DA thinks that they have that scientific information,

Morgan Fox:

They think they do, and they want every opportunity to show it. And because they are the sole arbiters of the administrative judicial review, they can make that last as long as they want in previous attempts. And NORML has been involved in rescheduling petitions since basically 1972, and this period has always lasted much longer than we thought it would. We’re talking years. So the DEA has the ability to make this period after the public comment last for as long as they want, and then after that, there’s an initial period of rulemaking and debate, and then once they make a final recommendation, there’s 30 days until it becomes law, at which point it is then able to be challenged through litigation before it really becomes a law. So we’re talking about a process that despite the fact that the Biden administration fast tracked its portion of it could potentially last years. So I just wanted to temper everyone’s expectations that this is something that’s going to happen immediately because it’s a long drawn out process that everybody that wants to see these changes happen is going to have to be involved in some fashion.

TG Branfalt:

I mean, but with your explanation, it doesn’t sound exactly like the monumental decision that the administration sort of pegged it as I

Morgan Fox:

Well, symbolically, I think it’s very, very important. This is the first time that any administration or HHS has said that cannabis does not belong in Schedule one, which we all know is the case. And it’s definitely the first time that the administration has fast tracked its portion of the review process after the notice of proposed rulemaking has happened. I think that solidly shows that the Biden administration is behind this change, but again, it’s going to take a while. So I think that we have to temper our expectations in that regard, but also we really need to think about what sort of practical changes a switch to Schedule three would actually have on both the industry as well as consumers and criminal justice.

TG Branfalt:

I do want to get to that, but let’s go back a little bit here. In layman’s terms, what would federal rescheduling actually do?

Morgan Fox:

Really the most notable change is that it would resolve, at least in theory, resolve the two 80 E tax issue for licensed cannabis businesses under the current two 80 E tax code. Legal cannabis businesses cannot deduct a lot of the same normal business expenses that any other industry can, resulting in an effective federal tax rate of sometimes up to like 70 or 80% if not more, in addition to all of the state taxes and local taxes and regulatory compliance costs that they have to deal with. Two 80 E is a big reason that most cannabis businesses are operating in the red right now and will continue to do so. It’s not the be all end all solution to their financial problems by any stretch of the imagination, but it does take a significant amount of heat off that. I think most importantly though, it’s to talk about what it doesn’t do, which is it does not harmonize state and federal cannabis law.

It does not all of a sudden make cannabis legal medically because in order to be in compliance with Schedule three, cannabis would have to be approved by the FDA. This is a process that could take 10. Well, first of all, it’s a process that the DEA or the F FDA A is not set up to handle. Cannabis is relatively unique and there’s no history within the FDA of approving a substance that has adult use purposes. It has medical purposes. It comes in many different forms. It’s a botanical substance, so it’s notable in any sort of a consistent manner. Basically, the FDA is not set up to deal with things like cannabis as it currently exists. It is definitely set up to deal with cannabinoid drugs that have been developed pharmaceutically such as Dronabinol, Marinol, ros, Epidiolex, et cetera. But in order to get those sort of specific cannabinoid pharmaceutical products approved takes tens to hundreds of millions of dollars and many years of approval process.

So it’s pretty clear that cannabis is not going to be approved as a plant medicine or just as a recreational plant or as a plant in and of itself by the FDA under its current structure, there is a lot of talk at the FDA to create a specific lane for cannabis or for specific cannabinoid products that would really encompass all of its different uses and all of its different formulations, but that has not really come to fruition yet. There’s congressional legislation that is looking at that, and I think folks at the FDA are also looking at that. But all that is to say that in order for even medical programs at the state level to be in compliance would, first of all, cannabis would have to be approved by the FDA, which is not going to happen under the current structure. And then if it was then all existing state systems regarding medical or even adult use would have to be completely broken down and start from scratch because cannabis would have to be sold in pharmacies instead of dispensaries.

It would have to be by prescription only. This is what Schedule three means for drugs from a consumer perspective, I think it’s also important to point out that Schedule three doesn’t really remove any significant barriers to research, which I know a lot of people have been talking about. It doesn’t do anything for the criminal justice aspect of cannabis at the federal level in terms of people continuing to get arrested or in terms of either pardons, expungements, clemency, sentencing, relief of any sort. And also there are a number of federal policies in place regarding employment suitability, security clearances, et cetera, that are specific to cannabis and are not related to the schedule whatsoever. That would also have to change. So a simple schedule change is really, I think, only going to impact the two 80 e tax code in any sort of a practical impact in the near term should it be approved, which is not a guarantee. And also that the time in which it would get approved is not a guarantee either.

TG Branfalt:

So I do want to ask you about the timing. Let’s say that this went beyond the whole process went beyond the election, and let’s say that Donald Trump, the Republican presumptive nominee were to be elected could with a sort of swipe of his pen, could he just say, no, we’re not doing this.

Morgan Fox:

I mean, he could certainly direct federal agencies to deprioritize it and in a different political environment might have a whole lot more power over exactly what they do. In particular, threatening to terminate the heads of agencies and organizations within the federal government. If they don’t comply, then the Biden administration currently has. So yes, I think it could get shut down or slowed down significantly. I think in that particular scenario, it really depends on whether or not a presumptive president Trump recognizes the political usability of allowing the process to go forward.

TG Branfalt:

Forward. And so you did mention that medical cannabis program, state cannabis programs would have to be broken down and start from scratch. Do you think that this is something that we really aren’t talking about? Because it is one of those things where when this was announced and I started talking to my friends who own shops and that sort of thing, and they said, oh, we’ll be able to two 80 E, and they talked about that, but I said, listen man, this could put you out of business effectively because of how schedule three, what’s under schedule three? Is that something that we are not talking about enough?

Morgan Fox:

I think we only have to worry about that if the federal government in particular DOJ and FDA decide that they want to really start enforcing it. DOJ has a current policy now of non-enforcement for people that are in compliance with state medical cannabis laws. That’s actually adjudicated by Congress in a recurring appropriations bill that actually prevents the Department of Justice from spending any money to go after people that are in compliance with state medical laws. And we’re in the process of trying to expand that to adult use programs. But aside from the medical part for adult use, DOJs policy has been since the Cole Memo and even after the recession of the Cole Memo from acting or then Attorney General Jeff Sessions to withdraw the Cole Memo, federal prosecutors have behaved relatively the same as under the Cole Memo, but there’s just a little bit less of an organization wide enforcement on that that could change if there is a change in administration and a change of Attorney General as we saw during the first Trump administration. But the bottom line is that unless there’s a huge uptick in enforcement from DOJ and FDA that states are going to continue doing what they have been doing, which is operating in violation of federal law.

TG Branfalt:

So regardless of this rescheduling proposition, the situation for cannabis businesses is still going to be precarious. Is that correct?

Morgan Fox:

I mean, as precarious as it always has been, it’s still in violation of federal law. There are going to be a number of factors that come into play regarding exactly how precarious it becomes over the coming months and over the next couple of years. But really it does not change things on the ground outside of the tax issue.

TG Branfalt:

And were you and NORML as an organization surprised at this action?

Morgan Fox:

I was surprised at how quickly the wheels of bureaucracy moved within the White House to approve it, that this is a major issue for the Biden administration and in particular vice President Kamala Harris, probably a little bit less so to the president himself, but it’s also an issue that the administration as a whole is really trying to make a standout issue to help attract younger voters. So I mean, I think that aside from the rescheduling conversation, it’s really important for us to continue putting pressure on the administration to do the things that it can do unilaterally, which is expand the scope of the pardons that it has already issued, start making stronger public statements about the need for descheduling and about the need for Congress to start enacting expungement provisions and things of that nature. But as I said, politically, it’s going to be very difficult for the administration to pull any levers in terms of the actual administrative process of schedule review after this point. The fact that they did so quickly I think is a really good sign that they’re in our camp and that they want to try to move this process along as quickly as possible, but now it’s not really in their hands anymore.

TG Branfalt:

And let me ask you about the impact, the overall impact of the, pardon that the pardons that President Joe Biden has given to federal cannabis people convicted of federal cannabis crimes. How much of a sort of was that revolutionary? I mean, how much of an impact did that really have because there’s not a whole lot of federal cannabis convictions for possession?

Morgan Fox:

Well, the estimates about how many individuals were impacted varies because in order to actually get the certificate, you had to individually apply. But all those pardons are in effect. It’s just that they might not necessarily impact somebody’s ability to get a job or to get housing or education unless they have the certificate and they have to go and try to get the certificate themselves. And so I think that additional promotion of the fact that a lot of folks that have these charges is really incumbent on the White House to do, and they’ve been doing a pretty good job of talking of this move and the president went so far as to then extend it a little over a year over or after the initial announcement in order to bring more people under the auspices of the pardon. But the pardon announcements have a very set date.

So anybody that gets arrested after the issue of events of the pardon is not eligible yet. We’re hoping to get expansion on that. But also it’s important to note that a pardon is not an expungement. So your arrest record at the federal level for a low level offense that may have been pardoned by the president is still going to show up in a background check. And you need to have that certificate there to show that it has been pardoned. And even then, it’s not an expungement, but we are talking about thousands of people that are eligible for this and that have been pardoned. Only a few hundred of ’em actually know about it yet and have gotten the certificates.

TG Branfalt:

So you’ve been in DC working on cannabis policy for the better part of a decade. Is this the most weed friendly administration during your time in Washington?

Morgan Fox:

Hands down.

TG Branfalt:

Hands down,

Morgan Fox:

Hands down.

TG Branfalt:

Is that a surprise?

Morgan Fox:

Do President has done more for cannabis policy reform than Joe Biden. Now there’s a lot more that he could do. There’s a lot more that he should do. But in terms of friendly administrations, this is really like a night and day change. During the Trump administration, we saw a few limited public statements and we saw a little bit of movement on criminal justice reform like the First Step Act, but a lot of it was really not focused on cannabis outside of a few pardons and clemency actions specifically directed towards some people that really, really, really deserved it. Folks like Walton Angelos and Alice Johnson. But in terms of mass actions, not really. And the first person that he put in charge of the DOJ was an avowed anti-cannabis drug warrior in Jeff Sessions. Admittedly, he fired him pretty shortly after he rescinded the Cole Memo and he put in somebody that for all of his potential faults and for all of his disagreements with the Trump administration, had made several statements that cannabis enforcement in legal states was not going to be a priority, which I think is a huge step in the right direction.

But yeah, if we’re really breaking it down, even if you go back to Obama, I mean during the first years of the Obama administration, we were still seeing massive raids in California of medical cannabis providers, violent SWAT raids. We never saw any public statements from the Obama administration that cannabis should be legal or that nobody should be put in jail for cannabis. I would like to see the Biden administration now that it’s admitted that nobody should be in jail for cannabis to extend that to nobody should be arrested for cannabis. But that being said, despite the fact that there’s a lot of things that the Biden administration can do in the next couple of months, and if it happens to win reelection for the next four years to improve upon its record, still more than any sitting president has ever done for this issue.

TG Branfalt:

And I want to talk to you about one of the bills in Congress that would legalize cannabis federally, the more act, again, you’re in Washington, you’re there in the sort of dirt of the Capitol. What are the odds that the more act could pass both chambers?

Morgan Fox:

Very good, but not in this current Congress. As I’m sure everybody listening knows, Congress is pretty dysfunctional at this point.

The idea of being able to pass comprehensive descheduling and regulatory legislation is slim to none. We might have some opportunities to be able to pass more incremental legislation like Safe Banking or Bills Protecting Second Amendment rights for lawful cannabis consumers or bills, protecting housing rights for lawful cannabis consumers, legislation that could potentially provide federal funding to states and localities that want to help expedite the expungement process at the local level. Because obviously most arrests happen at the state level. They don’t happen at the federal level. So providing resources to help expedite and move that process along are absolutely necessary, especially since a small amount of dollars go really, really far once you get the system automated. But in terms of passing standalone descheduling legislation, it’s just not going to happen in the current Congress. However, we do have an opportunity to try to get as many co-sponsors as possible on both the Moore Act and on the Senate side, the Cannabis Administration Opportunity Act, so that we can roll into the a hundred 19th Congress with a broader base of support and with enough support that we can actually get these bills introduced very early in the session and start fast tracking them.

TG Branfalt:

And you had mentioned the sort of incremental steps that we could take. In my sort of estimation, I believe that it’s going to be another 50 years before we get full federal legalization in Descheduling, and I think that we will get the maybe incremental steps like you mentioned. Is that me just being grim or what do advocates think about that?

Morgan Fox:

I think we’re on a much shorter timeline than that for Descheduling either administratively or through Congress. But I do think that it’s going to have to come through Congress, but I don’t think it’s going to take another 50 years. I am loathed to estimate exactly how long it could take because unfortunately cannabis is subject to a lot of political realities that are completely unrelated to cannabis that either lower its priority on the consideration scale or that cause people that might be supportive of cannabis policy reform to use it as a cudgel against people across the aisle or to try to attack their political rivals. And we saw a perfect example of this last year where a relatively innocuous veterans related study bill was passed in the Center of Veterans Committee. And then when that bill along with a bunch of other non-cannabis related veterans bills were brought up for a cloture vote to try to skip the whole process and just bring them to a vote. People that were on the Veterans Affairs Committee that voted in favor of that measure and others that were in the package voted no on bringing it to a cloture. And Senator John Corny from Texas was on record as saying that the reason for that was because they did not want to give Senator Tester from Montana who is a Democrat, a win when he was leading up to an election year. So unfortunately, cannabis is often the victim of things that are far beyond our control.

TG Branfalt:

And you had mentioned the Safe Banking Act, which the sort of short version is would allow cannabis companies access to traditional financial services. That legislation has passed the house, and I may correct me if I’m wrong here, six times, 7, 7, 7 times. Anyway, what is stopping it in Congress is it’s still just this politics sort of issue as you just alluded to.

Morgan Fox:

There’s a little bit of that, but also because in order for this to become law, I mean I think that if it were to come up for a vote in the Senate, it would probably pass, but there’s no solid pathway for it in the house right now because standalone legislation regarding cannabis or really related to anything other than appropriations is having a really hard time getting through the house just in terms of getting space on the schedule. As we get closer to the election, that time that’s available is going to be less and less. And also the focus on issues that are not purely political is going to be less and less.

TG Branfalt:

And even with, do you think that the odds are better? Were Democrats to have control of both chambers or because if they had a slim majority like the Republicans do now in the house, they maybe end up in the same sort of position where they’re again trying to, as you said, get standalone legislation through and they’re just not able to do it?

Morgan Fox:

Well, I mean the facts are on the table. We know that we have less co-sponsors in the GOP for any cannabis related bills than we do in the Democratic Party, with the exception of the Second Amendment bills, which me as a nonpartisan guy, but also as a Second Amendment fan are very much in favor of, because I don’t think that you should be treating people differently because they’re cannabis consumers, especially if they’re not medical patients. But by and large, there’s less support in Congress among the GOP than there are among Democrats. But even Democrats have been guilty of deprioritizing this issue when anything else that they feel is more important either politically or policy wise comes up. I think democratic control, both chambers would probably speed things along. But I’m curious about exactly how much I think that getting standalone legislation passed in any GOP controlled chambers in the next Congress is going to be difficult but not impossible, largely because I think that people are much more coming around to the idea that not only are these sensible policies, but also that they’re increasingly popular among their base regardless of political affiliation or political leanings.

For the last couple of years now, we’ve seen that a majority of Republicans support ending cannabis prohibition, and those numbers are climbing, especially among young voters. I think that if you’re looking at retaining power in either chamber or of the presidency, you really have to look to young voters because they’re the ones that turn out during presidential elections, which they will be doing in November. So changing, I’ll basically break it down like this. I think people that are opposed to cannabis policy prohibition or are trying to obstruct its path through Congress are going to increasingly see negative potentialities come true because of those decisions that are going to affect their ability to get reelected.

TG Branfalt:

So let me sort of switch gears a little bit here, but would the election of Trump change NORML’s game plan in 2025? And if so, how?

Morgan Fox:

Well, I mean there’s not a ton that we can do administratively, but politically I think it does kind of change the game plan a little bit and it would require us to put a lot more emphasis on the administration just because Republicans in Congress would largely be following Trump’s lead. That being said, I think that obviously this is not going to be a priority administratively for the Trump administration. So we have been traditionally focusing on Congress and taking the administrative changes as welcome changes and putting pressure on the administration to do what it can as we have with every administration before the Biden administration. So I think that that portion of it would probably stay the same. What it really means is a potential change in the nuances of how we go about trying to push this in Congress and trying to elevate this issue to a priority one and one that from our organizational perspective, protects consumers and public safety as its foremost.

TG Branfalt:

And just lemme ask you sort of personally, again, you’ve been in Washington for a long time working on these issues in different capacities. How has the anger politics or the way that the complete partisanship and sort of gridlock, how has that sort of changed your perception or your job in Washington in that role? It must have gotten harder.

Morgan Fox:

It has. It has because primarily legislators are not super interested in legislating, and that’s a problem when you’re trying to pass standalone legislation. But across the board, I think that a lot of folks are viewing this issue more through the lens of politics than they are through policy. And when it comes down to it, this is sound public policy, but we’re in a situation where a lot of people are acting reflexively on both sides of the aisle where if someone from party A says X and someone from party B says Y, then a lot of people just line up along those lines and don’t really think about what this actually is going to do for the American people.

TG Branfalt:

I mean, it is kind of wild too, to think that someone like Matt Gats conservative has tried to do a bit on cannabis policy, if you ask me anyway.

Morgan Fox:

Yeah, I mean there are a lot of folks, it’s a very, very big tent. People that want to see cannabis policy reform. A lot of it gets down to some of the nuances of it because unlike just a few years ago, lawmakers and their staff are much more informed about the nuances of cannabis policy and about its various effects on society and things like that. So they’re asking a lot harder questions, some of which we don’t have the research for, but we’re also seeing a lot less interest in moving these things unless they can be attached to some form of a political win for them. And if they can’t than the prioritization of that legislation starts to drop. We’re also seeing former bedfellows across the aisle. It’s probably a bad word to use for that, but former partners across the aisle sometimes getting into all sorts of issues with each other or potentially not pushing legislation that their major co-sponsors on or original sponsors on because of other political issues. I can think of a couple of examples right now, but there are some that even intraparty where if certain members that are considered problematic for basically either the establishment or that are burning bridges left and right are also on the bill, then there’s very much less likelihood that you’re going to get a whole bunch of sponsors from their party on that bill.

TG Branfalt:

And you mentioned that it’s that legalization or cannabis policy, I should say reforms are a big tent. What role, if any, do you think that sort of broad state laws, state law reforms have had on bringing people into that tent?

Morgan Fox:

They’ve definitely been useful, and I mean I think it’s really important that whether or not a federal lawmaker supports or opposes legalization, the simple fact of the matter is that once their state passes something, then it’s incumbent upon them to look out for the best interests of their state. In practice, that doesn’t always happen, but in theory that’s exactly what should happen and it does give us a little bit more of an in. So I mean as well as I do that states have always been leading the way on this, and we are getting close to, I mean, we’re already over 50% of the US population living in adult use states. Once we get to 50% of the states themselves having adult use, we might be in a slightly better position, but it’s certainly not guaranteed. I mean, a lot of people have been saying for the last 20 years that as soon as we get 25 states, then we’ll be able to flip this issue in Congress. And that’s just not the case. There are plenty of lawmakers that do not like legalization despite the fact that their state did it that are not only not necessarily going to vote for something that would help the cannabis consumers in their state or help support the laws within their state, but that also might not prioritize those issues.

TG Branfalt:

The insight on this is really great, and I really appreciate you being so forward with what you’re thinking on this. What is on or what legislation is on NORML’s agenda for next session? Regardless of the outcome of the election,

Morgan Fox:

All of it, every single piece of legislation that has been introduced in the hundred 18th, we want to see be reintroduced in the hundred 19th as soon as possible so that we can start having a substantive conversation about it in a new political paradigm. If one exists, I mean no matter what, it’s going to be a little bit different. So I want to see all those bills get reintroduced, but in particular, obviously the bigger descheduling bills as well as the incremental bills that we can maybe move a little bit more quickly while we’re talking about the larger issue of Descheduling at the federal level. Personally, I’m very invested in the housing legislation that was introduced by DC’s Delegate Holmes Norton and Senator Cory Booker. I’m very interested in the firearm and Second Amendment legislation. I’m very interested in the Veterans Access legislation and we’re seeing a lot of opportunities to be able to pass this legislation not just through the normal order as standalones, but also through appropriations, things like the Cure Act and improving suitability requirements for past cannabis users.

Obviously, we’d like to see that expanded to include current cannabis use in a rare moment of bipartisan support. We saw last September that a bill that was sponsored by Jamie Raskin and Nancy Mace the Cure Act, which as originally written, would have eliminated both past and current cannabis use from suitability for either federal employment or security clearances be cut down to just past use. But the trade off for that was that it passed through House Oversight Committee with flying colors in a hugely bipartisan vote. It was like 30 to 14 in a Republican controlled committee with a fairly staunch Republican Jim Comer as the head of that committee. So this is just an indication of what we can do through Compromise and bipartisan negotiations going forward. No matter who’s in charge, we can get a little farther down the road. Unfortunately, that Bill hasn’t moved since then, largely because the house has been tied up in all sorts of craziness. But we’re still seeing that Bill get additional. We’re still seeing Safe Banking get additional co-sponsors, and I think that if we can continue along this path of developing bipartisanship in the name of Sound public policy and avoid the politicization of cannabis, then we might be able to get a lot done in the next Congress and maybe a little bit done in this Congress.

TG Branfalt:

Morgan Foxman, I really appreciate you coming on the show as you are a wealth of knowledge and information. Morgan Fox is the political director of NORML, which has advocated for cannabis positive reforms since 1970. Where can people find out more about NORML and maybe get in touch with you?

Morgan Fox:

Well, you can go to NORML.org if you want to learn more about the issue or the organization. Feel free to send me an email at morgan@norml.org if you have any questions or just want to discuss the issues at hand. But I highly recommend people go to normal.org/act so that they can contact both their federal and state legislatures in support of sensible cannabis policy reform.

TG Branfalt:

Morgan, thank you so much for coming on the show. I appreciate you, appreciate all the work that you do in DC so people like me don’t have to go there.

Morgan Fox:

It is rough and super hot right now, but always happy to help out and anytime I can ever be of assistance, please lemme know.

TG Branfalt:

Appreciate you, man. You can find more episodes of the Ganjapreneur podcast and the podcast section at Ganjapreneur.com and wherever you get your podcasts. On the Ganjapreneur.com website, you’ll find the latest cannabis news and cannabis jobs updated daily along the transcripts of this podcast. You can also download the Ganjapreneur.com app in iTunes and Google Play. This episode was engineered by Wayward Sound Studio. I’ve been your host, TG Branfalt.

 

End


Missouri Health Officials Request Nearly $900k to Enforce Gov.’s Intoxicating Hemp Ban

The Missouri Department of Health and Senior Services (HSS) has requested nearly $900,000 to enforce Gov. Mike Parson’s (R) ban on intoxicating hemp products, according to the agency’s annual budget book. Parson signed the executive order banning the products in August but in a letter to the governor an attorney for HSS said the agency would not enforce large portions of the ban, rather focus on “the identification of ‘misbranded’ products.”   

Secretary of State Jay Ashcroft also rejected the executive order, saying that the emergency rules did not meet certain state law criteria and determining that the alcohol division could not legally conduct inspections, which left food inspectors to handle compliance. Ultimately, state officials created a joint task force to enforce the ban.   

The funding request by HSS aims to hire two full-time public health environmental specialists at $125,000 each and to contract five more inspectors at $400,000 a piece, with two of the contracted positions funded on a one-time basis “to stand up the program” at $150,000. The agency says the use of contractors is “preferred due to the expected decrease in market availability of this product over time.” 

The total request by HSS is $877,000. 

The agency estimates that there are 40,000 food establishments and smoke shops and 1,800 food manufacturers that could potentially be affected by the governor’s order, “but the majority of these facilities are at low-risk of requiring investigation.” 

In the request, HSS estimates that a staff of seven could conduct between 2,900 to 3,500 site visits annually. 

End


Delaware Receives 1,260 Adult-Use Cannabis Applications

Delaware’s Office of the Marijuana Commissioner has received more than 1,260 adult-use cannabis business applications ahead of the September 30 deadline, the Delaware News Journal reports. The state made more than $4 million from application fees as open application fees cost $5,000, microbusiness fees run $3,000 and social equity fees cost $1,000. 

The state will hold a lottery to deal out the licenses, the first round, for cultivation licenses, is set for October 24. The applications will first be reviewed by regulators. 

More than half of the applications were for “Open Retailer” and social equity retail licenses. Open licenses are for anyone, anywhere in the state. Social equity applications are designated for communities disproportionately affected by past cannabis laws and are intended to benefit people with past cannabis-related convictions and people who have lived for at least five of the past 15 years in “disproportionately impacted areas.” The applicant or someone in their immediate family must also have a prior cannabis-related conviction. 

A retail-only lottery is expected to take place in November or early December. Applicants that are selected in the lottery are given conditional licenses and then advance to a more rigorous second round. Applications from hopefuls that are not selected in the lottery will be kept if a second-round applicant is ultimately not awarded a license.   

End


West Virginia Supreme Court to Hear Case of Probationer Denied Medical Cannabis Access by Court

The West Virginia Supreme Court is set to hear the appeal of an individual on probation who was denied medical cannabis access by a judge, WV News reports. Kyle John Schober is currently serving probation for possession of cocaine with intent to deliver and, under West Virginia law, individuals on probation can’t violate federal or state law – and cannabis possession for any purpose remains federally illegal.  

In the Supreme Court filing on behalf of the state, Assistant Attorney General Jason David Parmer argues that the federal Controlled Substances Act’s “prohibition of marijuana trumps West Virginia’s authorization of medical cannabis because the ‘Supremacy Clause unambiguously provides that if there is any conflict between federal and state law, federal law shall prevail.’”   

“It is beyond peradventure that federal power over commerce is superior to that of the State to provide for the welfare or necessities of their inhabitants, however legitimate or dire those necessities may be.’ — Parmer, in a brief, via WV News 

Schober’s attorney, Assistant Public Defender Jonathan O’Dell, contends that the lower court’s decision to bar his client from medical cannabis access should be overturned due to the state’s statutory construction law, which is based on the principle that a law’s purpose is to reflect the intent of lawmakers and the courts are responsible for determining the intent of the General Assembly when it is important to apply statutory materials.   

O’Dell further argues that the 12-factor test provided to Schober “has no basis in West Virginia law or jurisprudence” and has resulted in a “subjective determination by the lower court that was almost impossible, if not impossible, for [Schober] to satisfy to the lower court’s satisfaction, and thus, was an abuse of discretion.” 

The case is expected to be heard on Wednesday. 

 

End


Pennsylvania Considers Expanding Who Can Officially Recommend Medical Cannabis

Pennsylvania could allow nurse practitioners and podiatrists to recommend patients to the state’s medical cannabis program under proposals awaiting approval from the state’s health secretary, according to a Spotlight PA report. The policy changes were recommended by the state’s Medical Marijuana Advisory Board and would add thousands more health professionals who are capable of making medical cannabis recommendations.

Nurse practitioners were originally unable to make recommendations for the Pennsylvania medical cannabis program but lawmakers gave regulators the ability to make such expansions down the line. Under the latest proposals, podiatrists would also be included — but only for severe, chronic, or intractable pain specific to the feet, the report said.

The proposals would still require nurse practitioners and podiatrists to apply and complete a four-hour training course before they could recommend patients for the program.

“What is Pennsylvania scared of? Is it the cannabis? Or is it the nurse practitioner? If you’re scared of either one of those, then you don’t understand either one of those.” — Nurse practitioner Judy Jenks, via Spotlight PA

The Pennsylvania Board of Nursing said last November that it supported letting nurse practitioners and podiatrists make medical cannabis recommendations, the report said.

The Bureau of Medical Marijuana’s director Laura Mentch previously noted that telehealth appointments have expanded the options for those seeking a practioner’s recommendation.

End


Campaign Seeks to Decriminalize Natural Psychedelics In Portland, Oregon

Activists in Portland, Oregon say they planning to put a ballot measure to decriminalize possession of naturally occurring psychedelics on local ballots in 2026, Marijuana Moment reports. The effort launched this year after lawmakers opted to undo the voter-backed drug decriminalization initiative that was passed in 2020.

Specifically, the Portland Psychedelic Health Act aims to make enforcement of drug laws relating to “naturally occurring” psychedelics the lowest possible priority for local police. The initiative would cover natural psychedelics like psilocybin mushrooms, ayahuasca, and mescaline, but not peyote, which is a federally protected cactus. The initiative would also establish a Psychedelics Advisory Panel to recommend new psychedelics-related guidances for the city.

“This Act recognizes that Portlanders have long consumed natural psychedelics for personal, health, and spiritual reasons, and that they will continue to do so. In addition to creating more safety and education around psychedelics, this Act protects the possession and use of these natural substances, making them the lowest priority for law enforcement in our city.” — Excerpt from the initiative

The campaign is set to begin gathering signatures in early 2025 to secure its spot on the 2026 ballot. Supporters of the initiative will need to collect about 40,000 votes, the report said.

The Portland campaign is supported by David Bronner, CEO of Dr. Bronner’s soap company, which previously gave $1 million to support the successful campaign to legalize medical psilocybin in Oregon.

Oregon was the first U.S. state to pass a blanket drug decriminalization policy in 2020 but, despite being approved by the majority of voters, lawmakers opted to walk back the policy this year. Oregon voted during the same election to also legalize the therapeutic use of psilocybin.

End


New York Officials Release Multi-Year Cannabis Industry Report

A three-year implementation report by the New York Office of Cannabis Management (OCM) and Cannabis Control Board (CCB) documenting the state’s adult-use cannabis reforms process was released on Thursday, highlighting industry trends, the successes and shortcomings of the state’s equity program, and more.

According to the report, 1,342 adult-use cannabis licenses have been issued, including more than 200 retailers, and 67% of New York-based cannabis consumers reported having purchased from a legal source. Additionally, the state-wide adult-use market generated $653.9 million in revenue in 2023.

The report also noted that 54.7% of the adult-use licenses have been awarded to applicants eligible for the state’s social equity program, surpassing the goal of 50% set by the state. However, only about 20 operators so far have utilized the Cannabis Social Equity Investment Fund.

New York’s legalization law includes expungement provisions covering more than 400,000 cannabis-related crimes, the report said, and more than 200,000 convictions have already been sealed, with another 107,000 awaiting sealing.

Tremaine Wright, Chair of the Cannabis Control Board, said in an introduction to the report that despite some “growing pains” for the industry — Gov. Kathy Hochul (D) earlier this year called the state’s adult-use roll-out a “disaster,” for example — the regulatory agencies “acknowledge the opportunities to build upon what we’ve started and look forward to continuous improvement and adaptation to meet the rapidly evolving needs of our cannabis community and industry.”

“I am proud to report that we continue to surpass our statutory goals in building a richly diverse and vibrant market. OCM has worked closely with us to design a dynamic and responsive licensing and compliance framework – true cornerstones of the market – which we continue to improve upon each and every day” — Wright, excerpt from the report

The report also noted that regulators have carried out 1,341 inspections on adult-use cannabis operators, leading to 1,135 violation notices. The report said that law enforcement has seized over 27,318 lbs. of unlicensed cannabis products since the industry’s launch, nearly $120 million worth.

End


Hopeful Cannabis Licensees Camp Out for 3 Weeks for First-Come, First-Serve Licenses

Cannabis operators pursuing a retail license in the Detroit, Michigan suburb of Redford have spent three weeks camping out in the line to apply, Crain’s Detroit Business reports.

The Redford Township area is one of the last jurisdictions in the area to allow adult-use cannabis sales and the competition for licenses there is steep. When the ordinance allowing adult-use cannabis sales was approved in the summer, local officials opted for a first-come-first-serve licensing process, which prompted hopeful licensees to begin lining up last month.

The report said dozens of cannabis operators were waiting in line by the time the application window opened on Thursday morning — and only about 12 licenses will be awarded in Redford due to local zoning restrictions on cannabis businesses.

A business leader in the line told Crain’s they had spent an extra $22,000 covering the wages of their employees as they work in shifts to maintain the company’s spot in line. Redford Township Clerk Gary Christie told WXYZ that the line started on September 10.

Meanwhile, Michigan cannabis sales are booming throughout the state: state-licensed retailers set another new sales record with $295.4 million in August, and the average price-per-ounce recently dropped to an all-time low of less than $80. In March, the Michigan cannabis industry sold more products than any other state, beating out California for the first time in monthly licensed cannabis sales.

 

End


House Democrats Call for ‘Swift Action’ on Cannabis Rescheduling

In a letter to Drug Enforcement Administration (DEA) head Anne Milgram, Congressmen Jarrold Nadler (D-NY) and Fran Pallone Jr., (D-NJ) called for “swift action” by the agency to transfer cannabis from Schedule I to Schedule III of the federal Controlled Substances Act (CSA). 

Nadler is a ranking member of the House Committee on the Judiciary, while Pallone, Jr. is a ranking member of the chamber’s Committee on Energy and Commerce.

“We value the Department of Justice’s steadfast commitment to prevent the misuse and diversion of controlled substances that pose a threat to public health. Amidst a devastating opioid and overdose crisis, it is imperative that law enforcement and public health agencies focus efforts on the biggest threats to Americans. When Congress passed the CSA, it recognized that our scientific and medical understanding is constantly evolving and granted the Attorney General and the Secretary of [Health and Human Services] important responsibilities in ensuring that the law reflects this knowledge.” — Nadler and Pallone Jr. in the letter  

In October 2022, President Joe Biden (D) directed the Justice Department to initiate the process to make the change. In May, the agency began that process, which Biden described at the time as “monumental.” As part of the proposal, the DEA opened a public comment period and, according to a Headset analysis, nine out of the 10 comments backed the rescheduling plan, with many calling for descheduling cannabis entirely.  

The DEA has set the rescheduling hearing for December 2 – less than a month after the election. 

End


Arkansas Ballot Initiative to Expand Medical Cannabis Access Fails to Qualify for November Ballots

The proposal to expand Arkansas’ medical cannabis program will not qualify for November ballots because advocates were short more than 2,000 signatures, the Associated Press reports. Secretary of State John Thurston on Monday said Arkansas for Patient Access had collected 88,040 of the 90,704 signatures needed to put the issue to voters. 

Arkansas for Patient Access has indicated it plans to take legal action against the decision. In a statement, the group called Thurston’s rejection of the signatures an “arbitrary” last-minute rule change. 

“The overwhelming support shown through the petition process proves that Arkansans want the opportunity to vote on expanded medical marijuana access. Arkansans for Patient Access will continue to fight for their right to make that decision at the ballot box this November.” — Arkansas for Patient Access in a statement 

In July, the state told the group it had fallen short of the signature goal but that the proposal had qualified for an additional 30 days to circulate petitions. 

The ballot initiative sought to allow registered patients to grow medical cannabis at home, certify additional health providers including osteopathic doctors, nurse practitioners, physician’s assistants, and pharmacists to recommend patients for the program, and allow such health providers to recommend medical cannabis treatments to anyone they think would benefit from the program. The initiative also includes telemedicine expansions, permits out-of-state patient IDs, increases the registration period for patients from one year to three years, and removes program application fees for patients. 

End


California Cannabis Enforcement Operation Seizes 2,652 Plants

California Gov. Gavin Newsom (D) on Monday announced that the state’s Unified Cannabis Enforcement Taskforce (UCETF) seized more than $2.3 million in illegally cultivated cannabis, including 2,652 plants in a single operation along with “multiple bags” of illegal pesticides. 

“Illegal cannabis from outside the safe, regulated market poses serious health risks and fuels criminal organizations responsible for devastating environmental damage.  I thank our state and local enforcement agencies for their collaboration in taking down this illegal enterprise, protecting both public safety and the environment from the harmful impacts of the illicit cannabis market.” — Newsom in a statement 

During the operation, UCETF removed nearly 117 pounds of processed cannabis flower and 2,652 cannabis plants that were cultivated in an industrial building, along with several containers of harmful pesticides. One person was arrested for the unlicensed cultivation of cannabis, unlicensed possession of cannabis for sale, maintaining a drug house, and possession of an unregistered pesticide.   

In a statement, Department of Pesticide Regulation Deputy Director of Enforcement Ken Everett said “It is critical that any pesticide used on cannabis is registered and all laws and regulations are followed.”  

“Enforcing these laws protects people and the environment from potential risks and impacts associated with pesticide use,” he said.   

According to the Governor’s Office, since its inception, UCETF has seized over $465 million in unlicensed cannabis by serving 309 search warrants. The task force has also eradicated 470,435 illegal cannabis plants, seized 150 illegal firearms, and arrested 38 individuals. 

End


California Gov. Signs Bill to Let Cannabis Cafes Serve Food & Host Live Music

California Gov. Gavin Newsom (D) signed a bill on Tuesday to let cannabis cafes in California serve food and drink and host live performances, the San Francisco Chronicle reports. This comes one day after he vetoed a bill that would have allowed small cannabis growers to sell products directly to consumers.

Authored by Assemblymember Matt Haney (D), the latest proposal addresses concerns the governor expressed last year when he vetoed the state’s previous proposal to legalize cannabis lounges. At the time, Newsom said that allowing such businesses “could undermine California’s long-standing smoke-free workplace protections” — so this year’s proposal carries requirements for participating companies to evaluate their working conditions and post appropriate warnings, and for local authorities to consider setting new ventilation and/or filtration requirements.

“Lots of people want to enjoy legal cannabis in the company of others. That is now finally legal in California and there’s no doubt that cannabis cafes will bring massive economic, cultural and creative opportunities and benefits to our state.” — Haney, via the San Francisco Chronicle

The rules will take effect starting January 1, 2025, giving jurisdictions the time to establish their own local rules for handling and/or allowing the state-legal cannabis cafes.

The bill, which was backed by the United Commercial and Food Workers union, passed the Assembly 63-5 and passed the Senate 30-7.

Previously, state law permitted on-site cannabis consumption but the businesses were not allowed to sell other types of consumables, such as infused food or beverages.

 

 

 

 

End


Kamala Harris Says ‘We Need to Legalize’ Adult-Use Cannabis

For the first time since becoming the Democratic nominee for president, Vice President Kamala Harris (D) voiced her opinions on cannabis reforms, reaffirming in a podcast interview released Monday that she believes in legalizing adult-use cannabis.

“I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior,” Harris told the hosts of “All the Smoke,” a sports podcast.

“I just feel strongly people should not be going to jail for smoking weed. And we know historically what that has meant and who has gone to jail.” — Harris, in the interview

Despite her early career as a prosecutor responsible for jailing many cannabis offenders, Harris first endorsed the full legalization of cannabis while serving as a U.S. Senator for California.

Harris’s position on cannabis policy goes further than that of President Joe Biden, who this year initiated the rulemaking process to move cannabis from Schedule I to Schedule III under federal law.

Meanwhile, the vice president’s opponent in this year’s presidential race, former President Donald Trump (R), last month announced a major shift in his opinions on cannabis policy, saying that he supports the federal rescheduling of cannabis to Schedule III and giving cannabis companies access to banking services. Trump also said that he is planning to vote “yes” on Amendment 3, Florida’s adult-use cannabis legalization amendment, during the election this November.

Notably, recent polling suggests that voters in several key battleground states strongly favor the legalization of medical and adult-use cannabis; poll respondents also said they supported giving the industry access to traditional banking.

End


Elevate Holistics Expands Telehealth Medical Marijuana Recommendation Services to Three New States

Elevate Holistics, a leading telemedicine platform, is thrilled to announce the expansion of its medical marijuana recommendation services to three new states: Arizona, Minnesota, and Connecticut. The brand’s goal has always been to make medical cannabis more accessible through telehealth solutions — and this expansion aims to do just that.

Elevate Holistics has helped over 125,000 people get their MMJ cards nationwide. Now, this expansion into AZ, MN, and CT will allow even more residents to conveniently obtain medical marijuana certifications from the comfort of their homes. The company’s user-friendly platform connects patients with expert MMJ doctors who can quickly and efficiently evaluate their eligibility for medical marijuana in compliance with specific state laws.

Not only will residents in these new states gain access to medical cannabis more easily, but they can also get help with the state registration portion of the MMJ process. With Elevate Holistics’ Full-Service add-on, the team helps patients register with the state’s medical marijuana program, making the final steps as straightforward as possible.

Even though recreational cannabis is legal in these states, having a medical marijuana card grants patients access to lower tax rates, medical-only discounts, and often higher allotments due to medical conditions.

For those in Arizona, Minnesota, or Connecticut looking for a trusted and convenient way to obtain a medical marijuana card, Elevate Holistics offers a solution that is both legitimate and accessible. The entire process, from consultation to certification, is completed online in minutes, making it easier than ever for patients to get the medical cannabis they need.

For more information on how to obtain a medical card from Elevate Holistics, or the other states the company services, visit elevate-holistics.com.

About Elevate Holistics:

Elevate Holistics is a pioneering telemedicine platform dedicated to assisting patients in securing medical cannabis certifications. With a commitment to quality, convenience, and patient satisfaction, Elevate Holistics has been at the forefront of making medical cannabis accessible to over 125,000 patients and counting. By leveraging state-of-the-art technology and medical expertise, Elevate Holistics ensures a seamless, efficient, and compassionate experience for all patients in 20 different states across the US.

End


Ohio Adult-Use Cannabis Sales Exceed $76.2M in Under Two Months

Adult-use cannabis sales in Ohio have exceeded $76.2 million in under two months of sales, according to Division of Cannabis Control (DCC) data. Since the launch of adult-use sales in August, retailers in the state have sold 8,813 pounds of “plant material” and 1,187,395 units of manufactured products.

The average price for cannabis products continues to drop month-over-month with the average cost per gram falling from $24.24 per one-tenth of an ounce of flower from the first week of September to $23.74 during the second week. The average price per gram of flower fell from $8.57 to $8.39 during that same timeframe, while the manufactured product sales average fell from $30.39 to $30.04. 

Currently, there are 124 dispensaries in the state that are licensed to sell both medical and non-medical cannabis products. According to Ohio State University’s Moritz College of Law, as of September 23, 111 municipalities and townships have passed moratoriums prohibiting adult-use cannabis businesses from operating within their borders. Most of those bans are in communities with a population of 10,000 or less. Twenty-five are in communities with a population between 10,001 and 20,000; 27 are in communities with a population between 20,001 and 50,000; and six in communities with a population of 50,000 or more. 

Major cities in the state host the most adult-use dispensaries, according to the college: Columbus has 13, Cincinnati has 10, Dayton has six, and Cleveland has five.  

End


Vermont Regulators Pause Accepting New Retail Cannabis Licenses

Vermont regulators last week paused accepting new cannabis retail and some cultivation applications, WCAX reports. Cannabis Control Board Chair James Pepper said the decision is meant to curb the “problem of retail saturation.” 

“You can’t get a bank loan to start a cannabis company. You can’t have a line of credit to make ends meet at the end of the month. If you’re short on cash, you don’t have bankruptcy protection. You have to pay exorbitant taxes. You can’t write off the normal business expenses that you would if you were any other business. And so you kind of stack all those up, and it’s a very challenging market.” — Pepper to WCAX 

Pepper told VT Digger that there is a “really unnatural distribution” of retail licenses in the state due, in part, to the number of communities – about 30% – that prohibit their operation. In all, there are more than 80 dispensaries in the state. 

In just under two years, the state has issued just over 90 retail cannabis licenses. Individuals looking to apply for a retail license or tier two cultivation licenses – which allow cultivation up to 2,500 square feet – have until November 15 before the board imposes the pause. 

Since October 2022, only two cannabis retailers have gone out of business in Vermont, the report says. There are 10 dispensary applications still pending.  

End


Judge Allows Parts of Lawsuit Challenging Medical Cannabis Petitions to Move Forward

A Lancaster County, Nebraska judge is allowing parts of the lawsuit challenging the two petitions to legalize medical cannabis to move forward, WOWT reports. In an order last week, Judge Susan Strong said that while the petitions had cleared the state’s “single-subject” rule and that they did contain enough information about the sponsors, the claim that Secretary of State Bob Evnen failed to strike duplicate signatures would be allowed to proceed in court. 

The lawsuit was filed earlier this month by John Kuehn, a former State Board of Heath member, veterinarian and rancher who has opposed any form of cannabis legalization.  

In the order, Strong noted that precedent would allow some clerical and technical errors to be disregarded if that information could be inferred from other evidence in the petition, such as the date it as signed, but that it was important to determine whether the alleged errors fell into that category, and allowed the two counts on signature disputes to proceed to arguments.    

In a statement, Crista Eggers, with Nebraskans for Medical Marijuana, said the groups was “grateful” for Strong’s “decision to dismiss the single subject and sponsor sufficiency claims against our ballot initiatives today” and that the organization “will continue to exercise all legal options” in the challenge against the signatures.  

End


DEA Wants More Psychedelics for Research Purposes

The Drug Enforcement Administration (DEA) last week proposed increasing its 2024 production quotas for research-grade psychedelic compounds including psilocybin, psilocin, and ibogaine, according to a Lucid News report.

The revised production agenda, posted in a notice to the Federal Reserve, calls for increasing production of from 20,000 to 30,000 grams of psilocybin and from 24,000 to 36,000 grams of psilocin, a 50% overall increase. The numbers also represent DEA’s new production quotas for those substances for 2025.

The agency also called for increasing ibogaine production in 2025 from 150 to 210 grams but did not call for increasing the production of MDMA or DMT, the report said.

The agency said the increased production rates are necessary to drive and support new research into the effects and potential applications of psychedelic substances, many of which are Schedule I substances under federal law.

“These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA’s support for research with schedule I controlled substances. The proposed increases reflect research and development needs as part of the process for seeking the FDA approval of new drug products.”  — Excerpt from the DEA notice

Previously DEA announced massive boosts to its psychedelics production rates in 2022 in preparation for a significant research push. The agency has also proposed decreasing next year’s production rates of fentanyl, hydrocodone (for sale), hydromorphone, and oxycodone (for sale).

Additionally, the FDA recently awarded “breakthrough therapy” designations to both psilocybin and MDMA — although the agency later highlighted concerns about the initial investigations into MDMA as a potential treatment for post-traumatic stress disorder (PTSD).

End


Ukraine Sets Medical Cannabis Qualifying Conditions

Officials with Ukraine’s Ministry of Health have approved a list of health conditions to qualify patients for the country’s new medical cannabis program, Marijuana Moment reports.

Per the rules, the program covers about 20 conditions including cerebral palsy, childhood epilepsy, chemotherapy-related complications, neuropathy, shingles, Parkinson’s disease, and weight loss due to eating disorders. The program does not specifically list post-traumatic stress disorder (PTSD) as a qualifying condition despite messaging by supporters, including President Volodymyr Zelensky, that suggested medical cannabis would be available to those affected by the country’s ongoing war with Russia, which invaded Ukraine in 2022.

Health officials can add additional qualifying conditions down the road.

The new cannabis program was signed into law by the president earlier this year and took effect last month. Under the law, the Agrarian Policy Minister will set cannabis cultivation and processing regulations, and the National Police and State Agency will regulate the distribution of medical cannabis products.

President Zelensky said during an address to Parliament last year that the country should employ “all the world’s best practices,” specifically calling to “finally fairly legalize cannabis-based medicines for all those who need them, with appropriate scientific research and controlled Ukrainian production.”

Zelensky also voiced support for the legalization of medical cannabis during his 2019 campaign for president.

 

End


FBI: Over 200K Cannabis Arrests in 2023, Racial Enforcement Disparity Continues

In 2023, U.S. law enforcement made over 217,000 arrests for marijuana-related offenses, with possession alone accounting for 84 percent of those arrests, according to new data from the FBI. While this marks a slight decrease from the previous year, when over 227,000 marijuana arrests were reported, advocates argue that the numbers are still unacceptable given the growing public support for legalization.

In addition, the new data reveals that racial disparities in enforcement remain an ongoing issue. Black Americans, who represent about 13.6 percent of the U.S. population, accounted for 29 percent of drug arrests in 2023, according to the data. This is consistent with long-standing evidence that people of color are disproportionately targeted for cannabis-related offenses, even though usage rates between racial groups are similar.

Although the data shows a slight decline in cannabis arrests from the previous year, NORML’s Deputy Director Paul Armentano pointed out that the data provided by the FBI is incomplete. “At a time when voters and their elected officials nationwide are re-evaluating state and federal marijuana policies, it is inconceivable that government agencies are unable to produce more explicit data on the estimated costs and scope of marijuana prohibition in America,” he stated. The specific issues highlighted by NORML include:

  • Incomplete Reporting: Some law enforcement agencies do not report crime data to the FBI, leading to an undercount of cannabis-related arrests. For 2023, 10% of agencies failed to submit data, covering 6% of the U.S. population.
  • Inconsistent Data: The FBI’s reporting contains discrepancies, with varying arrest numbers across different sections of their report, making it hard to draw consistent conclusions.
  • Unclear Classification: A category for “unspecified drug abuse violations” includes over 53,000 arrests, making it unclear how many of these might involve marijuana.
  • Inadequate Coverage of Federal Data: The DEA’s annual report on federal marijuana arrests and seizures for 2023 has not been released, leaving a gap in understanding national cannabis enforcement trends.
  • Estimation Procedures: FBI estimates some figures using data from participating agencies, meaning the total number of arrests is not an exact count but an approximation, further complicating the assessment of cannabis enforcement.
  • Impact on Policy: The incomplete and inconsistent data hinder the ability to accurately assess the scale and costs of prohibition, complicating efforts to reform cannabis laws and address the consequences of criminalization.

With a growing consensus among voters and political leaders favoring legalization, calls to address the inequities in cannabis enforcement are intensifying. Both current U.S. Presidential candidates have called for cannabis to be legalized, and a DEA hearing regarding the proposed reclassification of cannabis as a Schedule III substance under the Controlled Substances Act is scheduled for December 2nd.

End


Report: Federal Government Should Play Larger Role in Cannabis Reforms

A recent report sponsored by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) says the federal government should play a larger role in cannabis policy. The report, Cannabis Policy Impacts Public Health and Health Equity, appeared in the 2024 National Academies of Sciences, Engineering, and Medicine edition.

Dr. Steven Teutsch of the University of Southern California, the committee chair behind the report, told the Associated Press, “We’d like the federal government to step up to provide some leadership in this area.”

“While ongoing research is crucial, applying the core public health functions — assessment, policy development, and assurance — now will lead to better and more consistent policies for cannabis legalization and improved public health and health equity.” — Excerpt from the report

The report recommends that federal agencies like the NIH and CDC support a cannabis research agenda, monitor state legalization experiments, and create regulatory best practices with an emphasis on reducing youth access. For Congress, the report recommends closing the Farm Bill loophole which allows intoxicating, hemp-derived THC products at the federal level, and removing federal barriers to cannabis research. For jurisdictions with state-level cannabis reforms, the report recommends cannabis retail worker training and certification requirements, the automatic expunging of low-level cannabis offenses, and adopting and enforcing the quality standards for medicines and dietary supplements set by the U.S. Pharmacopeia.

Cannabis is still strictly prohibited under federal law but the Biden Administration announced plans in May to move cannabis to Schedule III, which would keep cannabis federally illegal but at a less-restricted level. The DEA has scheduled a December 2 hearing for expert testimony on the issue.

End